Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Baker Donelson handles Biotechnology & Pharmaceuticals, with 8 pending office actions and 2415 career applications. The current docket is limited compared with the firm’s recorded application volume, placing the active matters within a much broader prosecution history.
The resolved allowance rate is 86.46%, and the average is 3.15 office actions per allowance. Resolved applications have often reached allowance, while the action average indicates that multiple examination exchanges are typical. Practitioners should plan responses around both the favorable allowance pattern and the technical distinctions required for biotechnology and pharmaceutical claims.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (12%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
| No statute on record | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HENLEY III, RAYMOND J | 1 | 83.5% | +2.3% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | MONTANARI, DAVID A | 7d |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 18692097 | ANTI-CD3 ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | JADHAO, SAMADHAN JAISING | — |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CANELLA, KAREN A | — |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Pharmacosmos Holding A/S | 2 |
| ADIMAB LLC | 1 |
| Dartmouth College | 1 |
| Chinese Academy of Sciences | 1 |
| MACROGENICS, INC. | 1 |
| Immunext, Inc. | 1 |
| BEIJING TIDE PHARMACEUTICAL CO., LTD. | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1629 | 1 |
| 1623 | 1 |
| 1632 | 1 |
| 1672 | 1 |
| 1647 | 1 |
| 1627 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19361222 | TREATING IRON DEFICIENCY WITH FERRIC CARBOXYMALTOSE | Pharmacosmos Holding A/S | HENLEY III, RAYMOND J | 1629 | Other | Non-Final OA | — | Pending | Oct 17, 2025 |
| 18692097 | ANTI-CD3 ANTIBODIES | Adimab, LLC | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§112Other | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | Pharmacosmos Holding A/S | BERRY, LAYLA D | 1623 | §102§103§112DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | The Trustees of Dartmouth College | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | 7d | Pending | Nov 13, 2023 |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | Institute Of Zoology, Chinese Academy Of Sciences | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Macrogenics, Inc. | BUNNER, BRIDGET E | 1647 | Other | Final Rejection | 28d | Pending | Mar 06, 2023 |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. | CANELLA, KAREN A | 1643 | §112DP | Non-Final OA | — | Pending | Oct 21, 2022 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. | PECKHAM, RICHARD GRANT | 1627 | — | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial86.5% of resolved applications prosecuted by Baker, Donelson, Bearman, Caldwell & Berkowitz, P.C. were allowed, across 2,415 applications in USPTO records.
3.15 office actions per allowed application on average.
8 pending office actions as of October 2026, for 7 clients, before 8 examiners in 7 art units.
